The underwriters for Praktikertjänst-backed Aprea Therapeutics have taken up the over-allotment option in full to boost proceeds to nearly $97.8m.

Aprea Therapeutics, the US-based cancer treatment developer backed by healthcare provider Praktikertjänst, yesterday increased its initial public offering to nearly $97.8m after underwriters took up the over-allotment option in full. The company had issued 5.7 million shares priced at $15 each last week, raising $85m and seeing shares rise more than a third to close…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.